{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:55:32Z","timestamp":1790920532919,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neuroinform."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Lecanemab, a humanized immunoglobulin monoclonal antibody, has been approved for the treatment of Alzheimer\u2019s disease (AD). Although clinical trials have demonstrated its favorable safety profile, real-world studies are crucial for identifying rare adverse events (AEs) and evaluating post-marketing safety. This study aimed to evaluate the safety of lecanemab by combining a clinical prospective, observational case cohort with data from the FAERS database, thereby providing a robust basis for the identification of potential safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective and observational study was conducted on patients with mild-to-moderate AD receiving lecanemab treatment at a tertiary medical center in China from July 2024 to February 2026. Extracted data included demographic characteristics, time to onset of AEs, and clinical symptoms. Exposure-adjusted incidence rates were calculated per 100 patient-years (PYs). Disproportionality analysis was performed using the US Food and Drug Administration Adverse Event Reporting System (FAERS), and safety signals for AEs observed in the cohort were evaluated utilizing reporting odds ratios (RORs) and proportional reporting ratios (PRRs). Additionally, data from these two real-world sources were compared and cross-validated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The single-center prospective study enrolled a total of 91 patients. The median duration of lecanemab treatment was 185\u202fdays. Thirteen AEs were recorded (56.48\/100 PYs), with the most frequent being amyloid-related imaging abnormalities-hemosiderin deposition (ARIA-H; defined as microhemorrhages and hemosiderin deposition) (12.39\/100 PYs) and infusion-related reactions (IRRs) (8.85\/100 PYs). In the FAERS database, the most frequently reported preferred terms (PTs) included headache, amyloid-related imaging abnormalities-edema\/effusion (ARIA-E), ARIA-H, and IRRs. The majority of AEs occurred within the first 1\u20132\u202fmonths after initiating lecanemab treatment (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f393, 45.65%). Furthermore, FAERS analysis revealed a potential safety signal for cerebral infarction. However, this finding must be interpreted cautiously due to the lack of complete data on traditional stroke risk factors and concomitant antithrombotic use in spontaneous reports.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this single-center prospective observational study, lecanemab demonstrated a generally favorable safety profile. Patients with AD aged 65 to 85\u202fyears represent a high-risk demographic for AEs. Particular clinical vigilance is required regarding the occurrence of AEs within the first two months of lecanemab initiation. Notably, ARIA (including both ARIA-E and ARIA-H) can occur at any phase during the treatment course.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fninf.2026.1977226","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:35:39Z","timestamp":1790919339000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of lecanemab in real-world patients with Alzheimer\u2019s disease: a prospective, observational case series supported by FAERS signal analysis"],"prefix":"10.3389","volume":"20","author":[{"given":"Haixia","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Sichuan Provincial People's Hospital East Sichuan Hospital & Dazhou First People's Hospital","place":["Dazhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingqi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhao","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Urology, Sichuan Provincial People\u2019s Hospital East Sichuan & Dazhou First People\u2019s Hospital, Dazhou City Traditional Chinese Medicine Industry Incubation Center, Dazhou City Traditional Chinese Medicine Research Center","place":["Dazhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/13554794.2025.2566151","article-title":"Multiple ischemic strokes in a patient treated with Lecanemab: a case report","volume":"31","author":"Alammar","year":"2025","journal-title":"Neurocase"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"155627","DOI":"10.1016\/j.prp.2024.155627","article-title":"Immunogenicity of monoclonal antibody: causes, consequences, and control strategies","volume":"263","author":"Asmani","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neuroscience.2024.08.008","article-title":"Alzheimer's disease and sleep disorders: a bidirectional relationship","volume":"557","author":"Chen","year":"2024","journal-title":"Neuroscience"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3174\/ajnr.A8469","article-title":"Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities","volume":"46","author":"Cogswell","year":"2025","journal-title":"AJNR Am J Neuroradiol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer's disease: the path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev Alzheimers Dis."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1002\/alz.13081","article-title":"Prevalence of Alzheimer's disease dementia in the 50 US states and 3142 counties: a population estimate using the 2020 bridged-race postcensal from the National Center for Health Statistics","volume":"19","author":"Dhana","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019","volume":"7","year":"2019","journal-title":"Lancet Public Health"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"8192","DOI":"10.1002\/alz.14223","article-title":"Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab","volume":"20","author":"Gibson","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e70084","DOI":"10.1002\/gps.70084","article-title":"Clinical evolution of neuropsychiatric symptoms in Alzheimer's disease and dementia with Lewy bodies in a post-mortem cohort","volume":"40","author":"Gibson","year":"2025","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4140\/TCP.n.2017.511","article-title":"AChE inhibitors and NMDA receptor antagonists in advanced Alzheimer's disease","volume":"32","author":"Glynn-Servedio","year":"2017","journal-title":"Consultant Pharmacist"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13024-025-00872-7","article-title":"A manifesto for Alzheimer's disease drug discovery in the era of disease-modifying therapies","volume":"20","author":"Hering","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"100541","DOI":"10.1016\/j.tjpad.2026.100541","article-title":"Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer's disease","volume":"13","author":"Iwata","year":"2026","journal-title":"J. Prev Alzheimers Dis."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"ENEURO.0088","DOI":"10.1523\/ENEURO.0088-24.2024","article-title":"What's in it for me? Contextualizing the potential clinical impacts of Lecanemab, Donanemab, and other anti-\u03b2-amyloid monoclonal antibodies in early Alzheimer's disease","volume":"11","author":"Jin","year":"2024","journal-title":"eNeuro"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"109737","DOI":"10.1016\/j.neuropharm.2023.109737","article-title":"Memantine: updating a rare success story in pro-cognitive therapeutics","volume":"244","author":"Karimi Tari","year":"2024","journal-title":"Neuropharmacology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1399121","DOI":"10.3389\/fphar.2024.1399121","article-title":"Alzheimer's disease and its treatment-yesterday, today, and tomorrow","volume":"15","author":"Kim","year":"2024","journal-title":"Front. Pharmacol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00275-0","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00415-025-13151-8","article-title":"Spatial navigation deficits in early Alzheimer's disease: the role of biomarkers and APOE genotype","volume":"272","author":"Lacz\u00f3","year":"2025","journal-title":"J. Neurol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jad.2025.01.022","article-title":"Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data","volume":"374","author":"Li","year":"2025","journal-title":"J. Affect. Disord."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ejmech.2018.09.031","article-title":"Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease","volume":"158","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1093\/brain\/awaf427","article-title":"Safety and short-term outcomes of lecanemab for Alzheimer's disease in China: a multicentre study","volume":"149","author":"Li","year":"2025","journal-title":"Brain"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/10600280231218253","article-title":"Lecanemab: a humanized monoclonal antibody for the treatment of early Alzheimer disease","volume":"58","author":"Park","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"100473","DOI":"10.1016\/j.tjpad.2025.100473","article-title":"Safety profiles of lecanemab: a systematic review and meta-analysis of randomized controlled trials and real-world evidence","volume":"13","author":"Qi","year":"2026","journal-title":"J. Prev Alzheimers Dis."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf151","article-title":"Persistence with anti-dementia medications: a systematic review and meta-analysis","volume":"54","author":"Sistanizad","year":"2025","journal-title":"Age Ageing"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2023.09.008","article-title":"Economic burden of Alzheimer's disease: a systematic review","volume":"40","author":"Tay","year":"2024","journal-title":"Value Health Regional Issues"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e70905","DOI":"10.1002\/alz.70905","article-title":"Long-term safety and efficacy of lecanemab in early Alzheimer's disease: results from the clarity AD open-label extension study","volume":"21","author":"van Dyck","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimer's Res. Ther."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e13231","DOI":"10.1111\/psyg.13231","article-title":"A case of severe ARIA with multiple infarctions and extensive microbleeds following lecanemab administration","volume":"25","author":"Yamazaki","year":"2025","journal-title":"Psychogeriatrics"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1080\/14740338.2025.2467180","article-title":"Safety issues of Donepezil combined with Memantine in Alzheimer's disease population: real-world pharmacovigilance","volume":"25","author":"Zeng","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e102020","DOI":"10.1136\/gpsych-2024-102020","article-title":"The China Alzheimer report 2025","volume":"38","author":"Zhi","year":"2025","journal-title":"General psychiatry"}],"container-title":["Frontiers in Neuroinformatics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fninf.2026.1977226\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:35:40Z","timestamp":1790919340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fninf.2026.1977226\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":34,"alternative-id":["10.3389\/fninf.2026.1977226"],"URL":"https:\/\/doi.org\/10.3389\/fninf.2026.1977226","relation":{},"ISSN":["1662-5196"],"issn-type":[{"value":"1662-5196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1977226"}}